Onychomycosis | A Drug Pipeline Analysis Report 2018 | Technavio
Aug. 02, 2018
LONDON--(BUSINESS WIRE)--Aug 2, 2018--Technavio has announced their latest drug pipeline analysis report on . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat onychomycosis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180802005927/en/
Technavio has published a new report on the drug development pipeline for onychomycosis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
Onychomycosis: Market overview
A fungal infection caused in the nails is called as onychomycosis. It is also known as Tinea unguium. Onychomycosis is a broad term and does not only include disease caused due to dermatophytes but also includes infections caused due to yeasts and saprophytic molds. The symptoms of onychomycosis include discoloration, flaking, and thickening. Onychomycosis can be treated with medication either oral or topical and applying nail lacquers to protect the nail plates of fingernails and toenails.
According to a senior market research analyst at Technavio, “There are three types of onychomycosis, which include distal and lateral subungual onychomycosis, proximal subungual onychomycosis, white superficial onychomycosis, and candida onychomycosis.”
Onychomycosis: Segmentation analysis
This pipeline analysis report segments the onychomycosis market based on therapies employed (monotherapy), RoA (topical, oral, subungual, and transdermal), therapeutic modality (small molecule, and peptide), targets (squalene epoxidase (SE), CYP51, succinate dehydrogenase, and cell membrane), MoA (SE inhibitor, CYP51 inhibitor, succinate dehydrogenase inhibitor, and cell membrane permeability enhancer), geographical segmentation (US, Germany, and others) and recruitment status (active, not recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on the route of administration, more than 68% of the molecules that are being investigated for the treatment of onychomycosis are topical drugs.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180802005927/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA SOUTH AMERICA AFRICA MIDDLE EAST
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES RESEARCH SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 08/02/2018 04:25 PM/DISC: 08/02/2018 04:25 PM